- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 27, 2024
Data Byte
EMA’s CHMP confirms non-renewal of Translarna, denies new medicines Nezglyal and Syfovre
On the positive side of the ledger, BMS’s CAR T therapy Abecma headed for a line extension
BioCentury | Oct 12, 2023
Distillery Therapeutics
An engineered antimicrobial peptide targeting bacterial β-lactamases TEM and SHV
BioCentury | Feb 11, 2022
Distillery Therapeutics
Indole-2-carboxylates for carbapenem-resistant Gram-negative bacteria
BioCentury | Sep 17, 2021
Translation in Brief
Entasis’ CARB-X-backed non-beta lactam antibiotic; plus Takeda, Amyndas and more
BioCentury’s roundup of translational news
BioCentury | Mar 20, 2021
Translation in Brief
A β-thalassemia gene therapy; plus a method to design antibiotic resistance factor inhibitors, Tonix to start trial of COVID vaccine and more
BioCentury’s roundup of translational news
BioCentury | Jun 4, 2020
Finance
Everest to fund late-stage trials with $310M mountain of fresh cash
Largest venture round yet for an Asian therapeutics play could tee up an IPO at a valuation in the billions
BioCentury | Dec 20, 2019
Tools & Techniques
Editing bacterial resistance via gene drives
UCSD study shows how gene drives could tackle antimicrobial resistance
BioCentury | Aug 22, 2019
Distillery Therapeutics
Treating carbapenem-resistant bacteria with the insect-derived thanatin
BioCentury | Jul 13, 2019
Product Development
Why Merck is in infectious disease for the long haul
New commercial incentives could reward Merck for staying the course in infectious disease
BioCentury | Apr 16, 2019
Company News
Achaogen files for bankruptcy amid continued headwinds for antibiotic developers
Items per page:
1 - 10 of 241